Portola Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PTLA)

$45.02 +0.11 (+0.24 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$45.02
Today's Range$44.61 - $45.98
52-Week Range$29.50 - $67.10
Volume775,191 shs
Average Volume926,051 shs
Market Capitalization$2.94 billion
P/E Ratio-10.42
Dividend YieldN/A
Beta1.18

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PTLA
CUSIPN/A
Phone+1-650-2446864

Debt

Debt-to-Equity Ratio0.24%
Current Ratio8.31%
Quick Ratio8.31%

Price-To-Earnings

Trailing P/E Ratio-10.4212962962963
Forward P/E Ratio-9.11
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.50 million
Price / Sales82.75
Cash FlowN/A
Price / CashN/A
Book Value$3.41 per share
Price / Book13.20

Profitability

Trailing EPS($4.32)
Net Income$-269,040,000.00
Net Margins-938.19%
Return on Equity-110.46%
Return on Assets-61.18%

Miscellaneous

Employees163
Outstanding Shares65,250,000

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.49) by $0.08. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company's revenue was down 58.9% on a year-over-year basis. During the same period in the prior year, the business posted ($1.64) earnings per share. View Portola Pharmaceuticals' Earnings History.

When will Portola Pharmaceuticals make its next earnings announcement?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Portola Pharmaceuticals.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2018?

8 equities research analysts have issued 12 month price objectives for Portola Pharmaceuticals' shares. Their predictions range from $53.00 to $75.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $68.17 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (2/13/2018)
  • 2. Cowen Inc analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board (Age 70)
  • William Lis, Chief Executive Officer, Director (Age 52)
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President (Age 53)
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development (Age 65)
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer (Age 45)
  • John Lawrence, Senior Vice President, Chief Medical Officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director (Age 56)
  • Laura A. Brege, Independent Director (Age 59)
  • Dennis M. Fenton Ph.D., Independent Director (Age 65)
  • Charles J. Homcy M.D., Independent Director (Age 68)

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.20%), Kornitzer Capital Management Inc. KS (1.27%), Fred Alger Management Inc. (1.16%), Wells Fargo & Company MN (1.05%), Deutsche Bank AG (0.97%) and Geode Capital Management LLC (0.95%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Guggenheim Capital LLC, Pinnacle Associates Ltd., Marcus Capital LLC, Alliancebernstein L.P. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Two Sigma Advisers LP, Artal Group S.A., Amundi Pioneer Asset Management Inc., Kornitzer Capital Management Inc. KS, UBS Asset Management Americas Inc. and GW&K Investment Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $45.02.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.94 billion and generates $35.50 million in revenue each year. The biopharmaceutical company earns $-269,040,000.00 in net income (profit) each year or ($4.32) on an earnings per share basis. Portola Pharmaceuticals employs 163 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 E Grand Ave Ste 22, SOUTH SAN FRANCISCO, CA 94080-4811, United States. The biopharmaceutical company can be reached via phone at +1-650-2446864 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Portola Pharmaceuticals (NASDAQ:PTLA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.882.88
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.17$75.00$67.67$65.83
Price Target Upside: 51.79% upside42.53% upside33.86% upside16.97% upside

Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History

Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Morgan StanleyLower Price TargetOverweight -> Overweight$74.00 -> $65.00LowView Rating Details
2/21/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$68.00 -> $53.00HighView Rating Details
2/20/2018OppenheimerSet Price TargetBuy$72.00HighView Rating Details
1/1/2018William BlairReiterated RatingBuyLowView Rating Details
12/28/2017CitigroupReiterated RatingBuy$74.00LowView Rating Details
12/1/2017Goldman Sachs GroupInitiated CoverageBuy -> Buy$75.00HighView Rating Details
6/26/2017CowenBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018        
11/6/2017Q3 2017($1.49)($1.41)$4.71 million$3.83 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
11/9/2015Q3 2015($1.24)($1.05)$2.40 million$2.91 millionViewN/AView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
11/5/2013Q3 2013($0.68)($0.53)$2.00 million$2.77 millionViewN/AView Earnings Details
8/15/2013($0.72)($1.47)$2.00 million$2.60 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates

2018 EPS Consensus Estimate: ($4.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.72)($1.25)($1.49)
Q2 20182($1.10)($0.15)($0.63)
Q3 20182($1.61)($0.92)($1.27)
Q4 20182($0.94)($0.56)($0.75)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 86.45%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Henry Ward WolffDirectorSell12,000$47.00$564,000.00View SEC Filing  
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.703,000View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.004,730View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.5018,333View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00706View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.0024,824View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.0029,824View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Portola Pharmaceuticals (NASDAQ PTLA) News Headlines

Source:
DateHeadline
Portola Pharmaceuticals (PTLA) PT Lowered to $65.00Portola Pharmaceuticals (PTLA) PT Lowered to $65.00
www.americanbankingnews.com - February 22 at 6:22 PM
-$1.52 Earnings Per Share Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter-$1.52 Earnings Per Share Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter
www.americanbankingnews.com - February 22 at 10:12 AM
Credit Suisse Group Analysts Give Portola Pharmaceuticals (PTLA) a $53.00 Price TargetCredit Suisse Group Analysts Give Portola Pharmaceuticals (PTLA) a $53.00 Price Target
www.americanbankingnews.com - February 21 at 11:10 PM
Portola Pharmaceuticals Inc (PTLA) Given Consensus Recommendation of "Buy" by AnalystsPortola Pharmaceuticals Inc (PTLA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 21 at 5:34 PM
AIMT Meets Study Goals, TTPH Keeps Hopes Alive, Opportunities Galore For TXMDAIMT Meets Study Goals, TTPH Keeps Hopes Alive, Opportunities Galore For TXMD
www.nasdaq.com - February 21 at 9:03 AM
Portola Pharma (PTLA) Announces CHMP of EMA Communicated Positive Trend Vote on MAA for Andexanet Alfa and Negative Trend Vote for BetrixabanPortola Pharma (PTLA) Announces CHMP of EMA Communicated Positive Trend Vote on MAA for Andexanet Alfa and Negative Trend Vote for Betrixaban
www.streetinsider.com - February 21 at 9:03 AM
Portola Pharmaceuticals (PTLA) PT Set at $72.00 by OppenheimerPortola Pharmaceuticals (PTLA) PT Set at $72.00 by Oppenheimer
www.americanbankingnews.com - February 21 at 8:46 AM
Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanPortola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
finance.yahoo.com - February 20 at 5:13 PM
Portola Pharmaceuticals (PTLA) Downgraded by Zacks Investment ResearchPortola Pharmaceuticals (PTLA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 18 at 10:54 PM
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
finance.yahoo.com - February 15 at 4:52 PM
Portola Pharmaceuticals (PTLA) to Release Quarterly Earnings on WednesdayPortola Pharmaceuticals (PTLA) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM
Q1 2018 EPS Estimates for Portola Pharmaceuticals Inc (PTLA) Cut by OppenheimerQ1 2018 EPS Estimates for Portola Pharmaceuticals Inc (PTLA) Cut by Oppenheimer
www.americanbankingnews.com - February 12 at 2:02 AM
Portola Pharmaceuticals Inc Expected to Earn FY2021 Earnings of $5.72 Per Share (PTLA)Portola Pharmaceuticals Inc Expected to Earn FY2021 Earnings of $5.72 Per Share (PTLA)
www.americanbankingnews.com - February 9 at 6:12 PM
 Brokerages Anticipate Portola Pharmaceuticals Inc (PTLA) Will Announce Quarterly Sales of $2.42 Million Brokerages Anticipate Portola Pharmaceuticals Inc (PTLA) Will Announce Quarterly Sales of $2.42 Million
www.americanbankingnews.com - February 7 at 10:00 AM
Portola Pharmaceuticals (PTLA) Upgraded by ValuEngine to "Hold"Portola Pharmaceuticals (PTLA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - February 4 at 5:02 PM
Portola Pharmaceuticals (PTLA) Shares Cross Below 200 DMAPortola Pharmaceuticals (PTLA) Shares Cross Below 200 DMA
www.nasdaq.com - February 3 at 4:14 PM
Portola Pharmaceuticals (PTLA) Shares Cross Below 200 DMA - NasdaqPortola Pharmaceuticals (PTLA) Shares Cross Below 200 DMA - Nasdaq
www.nasdaq.com - February 3 at 9:18 AM
Portola Pharmaceuticals Inc (PTLA) Given Average Rating of "Buy" by AnalystsPortola Pharmaceuticals Inc (PTLA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 27 at 5:34 PM
Portola Pharmaceuticals (PTLA) Lifted to "Sell" at BidaskClubPortola Pharmaceuticals (PTLA) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - January 27 at 12:52 AM
Portola Pharma (PTLA) Reports Interim Results from Ongoing Phase 3b/4 ANNEXA-4 Trials for Andexanet Alfa - StreetInsider.comPortola Pharma (PTLA) Reports Interim Results from Ongoing Phase 3b/4 ANNEXA-4 Trials for Andexanet Alfa - StreetInsider.com
www.streetinsider.com - January 24 at 8:03 AM
Commit To Purchase Portola Pharmaceuticals At $45, Earn 20.9% Annualized Using OptionsCommit To Purchase Portola Pharmaceuticals At $45, Earn 20.9% Annualized Using Options
www.nasdaq.com - January 23 at 5:28 PM
BidaskClub Downgrades Portola Pharmaceuticals (PTLA) to Strong SellBidaskClub Downgrades Portola Pharmaceuticals (PTLA) to Strong Sell
www.americanbankingnews.com - January 21 at 1:34 PM
Portola Pharmaceuticals (PTLA) and Immunomedics (IMMU) Financial SurveyPortola Pharmaceuticals (PTLA) and Immunomedics (IMMU) Financial Survey
www.americanbankingnews.com - January 21 at 3:26 AM
Where Portola Pharmaceuticals Inc (NASDAQ:PTLA) Stands In Terms Of Earnings Growth Against Its IndustryWhere Portola Pharmaceuticals Inc (NASDAQ:PTLA) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 20 at 10:23 AM
5 Biotech Stocks That Could Be Bought Out in 2018 -- The Motley Fool - Motley Fool5 Biotech Stocks That Could Be Bought Out in 2018 -- The Motley Fool - Motley Fool
www.fool.com - January 14 at 4:28 PM
Portola Pharmaceuticals Reaches 80-Plus Relative Strength Rating BenchmarkPortola Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 10 at 4:33 PM
Portola Pharmaceuticals (PTLA) Rating Lowered to Sell at Zacks Investment ResearchPortola Pharmaceuticals (PTLA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 7 at 11:12 PM
What You Must Know About Portola Pharmaceuticals Inc’s (NASDAQ:PTLA) Financial StrengthWhat You Must Know About Portola Pharmaceuticals Inc’s (NASDAQ:PTLA) Financial Strength
finance.yahoo.com - January 5 at 4:16 PM
Portola Pharmaceuticals Inc (PTLA) Expected to Announce Quarterly Sales of $2.42 MillionPortola Pharmaceuticals Inc (PTLA) Expected to Announce Quarterly Sales of $2.42 Million
www.americanbankingnews.com - January 4 at 10:26 AM
Portola Pharmaceuticals Inc (PTLA) Receives Consensus Recommendation of "Buy" from BrokeragesPortola Pharmaceuticals Inc (PTLA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 2 at 5:12 PM
Portola Pharmaceuticals (PTLA) Receives "Buy" Rating from William BlairPortola Pharmaceuticals (PTLA) Receives "Buy" Rating from William Blair
www.americanbankingnews.com - January 2 at 9:34 AM
Portola Pharmaceuticals (PTLA) Coverage Initiated at Goldman Sachs GroupPortola Pharmaceuticals (PTLA) Coverage Initiated at Goldman Sachs Group
www.americanbankingnews.com - December 30 at 5:14 PM
Q1 2018 Earnings Estimate for Portola Pharmaceuticals Inc (PTLA) Issued By William BlairQ1 2018 Earnings Estimate for Portola Pharmaceuticals Inc (PTLA) Issued By William Blair
www.americanbankingnews.com - December 29 at 11:00 AM
Stock Traders Purchase Large Volume of Put Options on Portola Pharmaceuticals (PTLA)Stock Traders Purchase Large Volume of Put Options on Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - December 29 at 1:58 AM
Oppenheimer Analysts Give Portola Pharmaceuticals (PTLA) a $80.00 Price TargetOppenheimer Analysts Give Portola Pharmaceuticals (PTLA) a $80.00 Price Target
www.americanbankingnews.com - December 28 at 7:14 PM
Citigroup Reaffirms "Buy" Rating for Portola Pharmaceuticals (PTLA)Citigroup Reaffirms "Buy" Rating for Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - December 28 at 1:40 PM
Portolas (PTLA) AndexXa BLA Review Period Extended by FDAPortola's (PTLA) AndexXa BLA Review Period Extended by FDA
finance.yahoo.com - December 27 at 4:58 PM
Portola Pharma (PTLA) Reports Update on Biologics License Application (BLA) for AndexXa (andexanet alfa)Portola Pharma (PTLA) Reports Update on Biologics License Application (BLA) for AndexXa (andexanet alfa)
www.streetinsider.com - December 27 at 4:58 PM
Portola's (PTLA) AndexXa BLA Review Period Extended by FDAPortola's (PTLA) AndexXa BLA Review Period Extended by FDA
finance.yahoo.com - December 27 at 4:58 PM
Company News For Dec 27, 2017Company News For Dec 27, 2017
finance.yahoo.com - December 27 at 12:41 PM
Heres Why Portola Pharmaceuticals Inc. Tanked as Much as 10%Here's Why Portola Pharmaceuticals Inc. Tanked as Much as 10%
www.fool.com - December 26 at 4:58 PM
Portola Pharma (PTLA) Reports Update on Biologics License Application (BLA) for AndexXa (andexanet alfa) - StreetInsider.comPortola Pharma (PTLA) Reports Update on Biologics License Application (BLA) for AndexXa (andexanet alfa) - StreetInsider.com
www.streetinsider.com - December 26 at 3:41 PM
Portola Pharma (NASDAQ:PTLA) Shares Under Pressure After FDA ... - BenzingaPortola Pharma (NASDAQ:PTLA) Shares Under Pressure After FDA ... - Benzinga
www.benzinga.com - December 26 at 3:41 PM
Here's Why Portola Pharmaceuticals Inc. Tanked as Much as 10%Here's Why Portola Pharmaceuticals Inc. Tanked as Much as 10%
finance.yahoo.com - December 26 at 3:41 PM
Portola Pharma Shares Under Pressure After FDA ExtensionPortola Pharma Shares Under Pressure After FDA Extension
feeds.benzinga.com - December 26 at 11:39 AM
Portola Pharma stock falls 7% after delay in FDA review - MarketWatchPortola Pharma stock falls 7% after delay in FDA review - MarketWatch
www.marketwatch.com - December 24 at 7:19 PM
Portola Pharmaceuticals: What The AndexXa Approval Delay Means? - Seeking AlphaPortola Pharmaceuticals: What The AndexXa Approval Delay Means? - Seeking Alpha
seekingalpha.com - December 24 at 4:47 AM
Portola Pharmaceuticals: What The Early FDA Approval Of Bevyxxa PAS Entails - Seeking AlphaPortola Pharmaceuticals: What The Early FDA Approval Of Bevyxxa PAS Entails - Seeking Alpha
seekingalpha.com - December 23 at 11:31 PM
Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018 - GlobeNewswire (press release)Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018 - GlobeNewswire (press release)
globenewswire.com - December 23 at 11:31 PM
Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa) - GlobeNewswire (press release)Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa) - GlobeNewswire (press release)
globenewswire.com - December 23 at 11:31 PM

SEC Filings

Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.